Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA

BACKGROUND: Precision medicine and customized therapeutics based on the features of each patient are important for maximizing therapeutic effects. Because most cases of HCC occur in the damaged liver through various etiologies, such as hepatitis virus infection, steatohepatitis, and autoimmune hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Funato, Kazuyoshi, Miyake, Nozomi, Sekiba, Kazuma, Miyakawa, Yu, Seimiya, Takahiro, Shibata, Chikako, Kishikawa, Takahiro, Otsuka, Motoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635605/
https://www.ncbi.nlm.nih.gov/pubmed/37938099
http://dx.doi.org/10.1097/HC9.0000000000000313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635605/
https://www.ncbi.nlm.nih.gov/pubmed/37938099
http://dx.doi.org/10.1097/HC9.0000000000000313

Ejemplares similares